ArticleBarrier immunity2025
RORγt-APCs: The New Masters of Oral Tolerance.
Article in Barrier immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Oral tolerance is defined by the hypo-responsiveness of our body to fed antigens, and its failure can lead to immune-mediated diseases, such as allergy, chronic inflammation and autoimmune diseases. Decades of research have demonstrated that antigen-presenting cells (APCs) promote oral tolerance by inducing regulatory T cells (Tregs) and/or suppressing T cell activation. Nevertheless, the exact subsets of APCs involved in the presentation of antigens to T cells remains under debate. Recent exciting studies have described several subsets of RORγt (Retinoic acid-related orphan receptor gamma t)-APCs that have key roles in regulating immune responses and oral tolerance. In this review, we briefly summarize the current knowledge about oral tolerance development and then focus on discussing how these newly identified RORγt-APCs act as crucial regulators of this process.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.